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Abstract 
Background: An increasing number of proteins are being shown to assemble into amyloid structures that lead to 
pathological states. Among them, mammalian prions outstand due to their ability to transmit the pathogenic con-
formation, becoming thus infectious. The structural conversion of the cellular prion protein (PrPC), into its misfolded 
pathogenic form (PrPSc) is the central event of prion-driven pathologies. The study of the structural properties of 
intracellular amyloid aggregates in general and of prion-like ones in particular is a challenging task. In this context, the 
evidence that the inclusion bodies formed by amyloid proteins in bacteria display amyloid-like structural and func-
tional properties make them a privileged system to model intracellular amyloid aggregation.
Results: Here we provide the first demonstration that recombinant murine PrP and its C-terminal domain (90–231) 
attain amyloid conformations inside bacteria. Moreover, the inclusions formed by these two PrP proteins display 
conformational diversity, since they differ in fibril morphology, binding affinity to amyloid dyes, stability, resistance to 
proteinase K digestion and neurotoxicity.
Conclusions: Overall, our results suggest that modelling PrP amyloid formation in microbial cell factories might open 
an avenue for a better understanding of the structural features modulating the pathogenic impact of this intriguing 
protein.
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Background
Protein aggregation is the hallmark of many neurodegen-
erative diseases, including Alzheimer’s (AD), Parkinson’s 
(PD), and the Transmissible Spongiform Encephalopa-
thies (TSEs) [1], also termed prion diseases. The mis-
folding of a particular protein, i.e., the β-amyloid peptide 
(Aβ) for AD, α-synuclein (α-syn) for PD, and prion pro-
tein (PrP) for TSEs can lead to its abnormal accumula-
tion in tissues, which usually comes along with severe 
cellular damages. Irrespectively of the misfolded pro-
tein sequence and structure, protein aggregation usually 
proceeds in a well-organized fashion to form amyloids in 
these diseases [1]. Amyloid fibrils architecture is charac-
terized by a β-sheet enriched core, which usually binds to 
Congo red (CR) and thioflavin-T (Th-T) dyes [2].
TSEs form a group of lethal neurodegenerative disor-
ders, which affect both humans and other mammals [3]. 
They may manifest as infectious, genetic or sporadic dis-
eases. The structural conversion of the cellular prion pro-
tein (PrPC), into its misfolded pathogenic form (PrPSc) 
is the central event of these pathologies. PrPC, which is 
found anchored to the extracellular membrane of several 
cell types, has a well-defined structure, with a highly flex-
ible and unstructured N-terminal tail and a globular C-ter-
minal domain composed by three α-helices and two short 
antiparallel β-strands [4, 5] (Fig. 1). Unlike PrPC, PrPSc is an 
insoluble protein, mainly composed by β-sheet structures, 
partially resistant to proteolysis, with a high propensity to 
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form both amorphous and amyloid-like aggregates [3, 6, 
7]. Deposition of aggregated PrPSc in tissues is attributed 
to cause neurodegeneration. PrPSc aggregation becomes 
self-perpetuating in  vivo through the conversion of host 
PrPC into abnormal PrPSc, in a process catalyzed by the 
infectious form [6, 7]. In vitro, the assembly of prions into 
amyloids displays a typical nucleation-elongation reaction, 
but in the presence of preformed fibrillar seeds the ‘lag-
phase’, corresponding to the nucleation reaction, is abro-
gated. The reduction in the lag-phase evidences the ability 
of the seed to catalyze amyloid polymerization [7–9], a 
property that underlies the mechanism of prion conforma-
tional replication [10]. It is assumed that the PrP can adopt 
multiple misfolded conformations that are the molecu-
lar origin of prion strains and dictate the efficiency of the 
species barrier in the transmission of prions [11]. Distinct 
prion strains can lead to phenotypically different prion dis-
eases in animals, with different incubation times and brain 
deposition profiles [12–14].
Inclusion bodies (IBs) formation in bacteria has long been 
regarded as an unspecific process resulting from the col-
lapse of hydrophobic contacts between partially or totally 
unfolded species after protein synthesis at the ribosome 
[15]. However, an increasing body of evidence indicates 
that the bacterial IBs formed by amyloidogenic proteins 
share a number of common structural features with the 
highly ordered and, in many cases, pathogenic amyloid 
fibrils [16–19]. Interestingly, it was shown that a specific 
domain of a bacterial DNA replication protein, the RepA-
WH1, assembles into fibrils and, when expressed in E. coli, 
can lead to a peculiar amyloidosis through the inhibition of 
bacterial proliferation [19]. These RepA-WH1 aggregated 
particles can be vertically transmitted across generations, 
thus this protein was characterized as a synthetic bacte-
rial prionoid [19]. Therefore, bacteria have become a sim-
ple model system to study intracellular protein aggregation 
under biologically relevant conditions that cannot be easily 
recapitulated in vitro, such as the presence of chaperones 
and proteases, molecular crowding, and the continuous 
synthesis of the protein in the ribosome [20–22].
Het-s, from the fungus Podospora anserina, was the 
first prion protein whose bacterial IBs were shown to dis-
play amyloid-like properties [23, 24]. The differential trait 
of these aggregates emerged when they were transfected 
into prion-free fungal strains, as they promoted prionic 
conversion [23]. This result was later corroborated for the 
yeast prion Sup35 [25, 26]. The amyloid-like IBs of Sup35 
induced the prion phenotype in prion-free yeast strains, 
the infectivity rate being modulated by the environmen-
tal conditions during the formation of IBs [25–27]. These 
observations provide perhaps the best evidence that the 
IBs molecular structure can recapitulate the architecture 
of amyloid fibrils, in such a way that even the infectious 
properties of amyloids, which depend on specific confor-
mational features, seem to be conserved in the two type 
of aggregates.
It was previously shown that bacterially expressed 
recombinant murine PrP can be turned infectious 
in vitro causing prion pathology when inoculated in mice 
[28]. Here, we address whether, like their fungal coun-
terparts, mammalian PrP can form amyloid intracellular 
aggregates when expressed in bacteria. With this aim, 
we produced, purified and conformationally character-
ized the intracellular aggregates formed by the wild-type 
murine PrP encompassing residues 23–231 (PrPWT) and 
the C-terminal domain of murine PrP (PrP90–231) (Fig. 1). 
Our current study provides the first demonstration that 
recombinant murine PrPs can form amyloid structures 
inside bacterial IBs. Besides, although possessing similar 
secondary structure, PrPWT IBs and PrP90–231 IBs exhibit 
conformational diversity, as they bind CR and Th-T dyes 
to different extents, display distinct morphology, differ-
ent stability and resistance against proteinase K proteoly-
sis. These conformational differences result in different 
toxicity of the two PrP IBs resistant cores when added to 
neuroblastoma cells in culture.
Results and discussion
Aggregation of PrPWT and PrP90–231 into IBs in bacteria
The inherent aggregation propensity of amyloid pro-
teins often results in their aggregation into insoluble 
Fig. 1 Mouse PrP structure and domain organization. a Three dimen-
sional structure of the globular domain of mouse PrP (only residues 
124–226 are assigned by NMR), PDB: 1AG2. Alpha helices 1, 2 and 3 
are represented in red; beta strands 1 and 2 in yellow; loops and turns 
in green. The dotted gray line represents the unstructured N-terminal 
domain, comprising residues 23–120 (figure done with PyMol and 
disordered domain drawn with Inkscape). b Scheme of the primary 
structure of mature murine PrP (residues 23–231). HD hydrophobic 
domain; β-sheets are depicted in yellow, α-helices in red, and the 
remaining of the C-terminal domain in green; N-181 and N-197 are 
sites of glycosylation; GPI glycosylphosphatidylinositol anchor; PK 
proteinase K cleavage site
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IBs when they are produced in bacteria [29]. In several 
cases, these intracellular aggregates have been shown 
to display amyloid-like properties. To verify if this is 
the case for mammalian prion proteins, we expressed 
the murine wild-type prion protein (PrPWT) encom-
passing residues 23-231 (PrPWT) and the C-terminal 
domain of murine PrP (PrP90–231) in bacteria and puri-
fied the resulting IBs. Both PrP forms [either the full-
length, mature PrP (PrPWT) or the truncated fragment 
90–231] can exist in vivo in healthy and diseased brain 
and have been extensively studied [30–32]. The N-ter-
minal unstructured domain is proposed to participate in 
PrP physiological function because of its ability to bind 
to different classes of partners, including copper ions 
(Cu2+), glycosaminoglycans (GAGs), nucleic acids (NAs) 
and lipids [33–38]. It is proposed that PrPC acts as cell 
surface scaffold protein, gathering different partners in 
a macromolecular assembly to participate in cell signal-
ling [39]. PrPC undergoes endoproteolytic attack within 
its N-terminal domain, leading to the appearance of 
C-terminal fragments attached to the plasma membrane 
and soluble N-terminal peptides [30]. Both in normal 
and pathological brains one of these cleavages occurs 
at position 90, thereby generating PrP90–231 C-terminal 
fragment. The truncated PrP encompassing residues 
90–231 corresponds to the proteinase K-resistant core 
of the pathogenic PrPSc, referred also as PrPRes [30]. 
Although the N-terminal domain appears to be unnec-
essary for prion propagation, since the fragment PrPRes 
is capable of transmitting prion disease in vivo [40]; this 
region may affect the pathways of prion misfolding and 
substantially impact PrPSc conformational diversity. Fur-
thermore, in vivo studies have shown that mice express-
ing N-terminally truncated PrP develop disease more 
slowly and are less susceptible to infection than mice 
expressing PrPWT [41].
PrP forms were expressed essentially as insoluble pro-
teins in bacteria, with only a small portion of the pro-
tein residing in the soluble fraction. Accordingly, IBs 
were purified from the insoluble cellular fraction (Fig. 2). 
PrPs were the major component in purified IBs, with 
PrPWT displaying a molecular weight of ~25 kDa and the 
PrP90–231 between 15 and 20 kDa, according to respective 
bands in SDS-PAGE (Fig.  2). The approximate molecu-
lar weights obtained from the electrophoresis gel are in 
accordance with the theoretical molecular masses for 
both PrPWT and PrP90−231 (23 and 16 kDa, respectively), 
with the addition of the histidine-tag (+~3  kDa) (see 
“Methods”). Further refolding, purification and cleavage 
steps allowed extraction of soluble and pure PrP from the 
IBs (see “Methods”) for subsequent in vitro fibril forma-
tion and seeding analysis.
PrPWT and PrP90–231 form β‑sheet enriched IBs
The aggregation of proteins into amyloid fibrils results in 
the formation of intermolecular β-sheets [16, 42]. Atten-
uated Total Reflectance–Fourier Transform Infrared 
spectroscopy (ATR-FTIR) permits addressing the struc-
tural characteristics of protein aggregates [43–46].
To get insights into the secondary structure content of 
the two purified PrP IBs, we analysed the amide I region 
of the FTIR spectrum (1700–1600  cm−1) (Fig.  3). This 
region corresponds to the absorption of the carbonyl 
peptide bond group of the protein main chain and is a 
sensitive marker of the protein secondary structure [47]. 
Deconvolution of the ATR-FTIR-absorbance spectra of 
PrPWT and PrP90–231 IBs allows us to assign the individ-
ual secondary structure elements and their relative con-
tribution to the main absorbance signal (Fig. 3; Table 1). 
In contrast to soluble purified PrPs, which exhibit a pre-
dominant α-helical secondary structure content (Addi-
tional file 1), as previously assessed by FTIR and circular 
dichroism [36, 48, 49], it is evident that the truncated 
form (PrP90–231) has a higher contribution of β-sheets 
(Fig. 3; Table 1). The low frequency peak at ~1620 cm−1 
together with the low intensity, high frequency band at 
~1690 cm−1 (band 1, Fig. 3a, b) are attributed to antipar-
allel beta-sheets found in fibrils [46]. In addition, the 
peak at 1634–1638  cm−1 (band 4, Fig.  3a, b) found in 
both IBs is assigned to parallel β-sheets, indicating a 
Fig. 2 Isolation of PrPWT and PrP90−231 IBs from E. coli cells. SDS-PAGE 
analysis of purified PrPs IBs. The band at ~16 kDa corresponds to the 
C-terminal region of PrP (PrP90−231) and that at ~25 kDa to the PrPWT 
(rPrP23−231), both with the histidine-tag. The purification of both PrP 
monomers from their respective isolated IBs is also shown, as well as 
the remaining soluble proteins present in the supernatant after cell 
fractionation (SN). Molecular weight markers are shown on the left 
(MW)
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mixed β-sheet composition for PrPs found in inclusion 
bodies. In general, the observed absorption FTIR spectra 
is similar to the one shown for prion rods extracted from 
scrapie-infected hamster brains [50]. As also seen for 
infectious prion rods [50], part of the native structure was 
maintained for both extracted IBs (peaks at ~1655 cm−1 
attributed to α-helical/disordered structure). Thus, we 
suggest that a fraction of the molecules are adopting the 
intrinsic native helical fold, since native protein structure 
has been described to be retained in the IBs formed by 
certain proteins, such as GFP and others [51, 52]. 
Amide I ATR-FTIR spectra deconvolution and band 
assignment was done as described in the Methods 
section with OMNIC™ software. Band frequencies devia-
tion: ±4 cm−1. The depicted wavenumbers refer to bands 
1–5 (from the higher to the lower frequency) obtained 
from Fig. 3.
Stability of PrPs IBs towards chemical denaturation
The presence of regular β-sheet secondary structure 
inside PrPs amyloid-like IBs implies the existence of 
cooperative interactions between the polypeptide chains 
embedded in these aggregates. To confirm this assump-
tion, we used chemical denaturation with urea. We have 
shown before that this approach allows approximat-
ing the conformational stability of bacterial intracel-
lular aggregates [53]. IBs solubilization was measured 
by monitoring the changes in absorbance at 350  nm in 
urea concentrations ranging from 0 to 8  M. The coop-
erative denaturation transitions observed for both PrPs 
IBs support the presence of selective contacts inside 
these aggregates (Fig. 4). We calculated [urea]1/2 for IBs 
solubilization to be 3.72 ±  0.10 and 2.61 ±  0.20  M, for 
PrPWT and PrP90–231IBs, respectively; exhibiting thus sig-
nificantly different conformational stability. The stability 
of these in vivo formed PrP aggregates is, however, lower 
than the one reported for in vitro formed PrPWT fibrils, 
with m1/2  ~  4.5  M in guanidine hydrochloride-induced 
denaturation experiments [54]. This is not surprising if 
we take into account that ordered and disordered confor-
mations appear to coexist in IBs and that the presence of 
minor concentrations of other proteins might also condi-
tion the stability of these in vivo formed aggregates.
PrPWT and PrP90–231 IBs bind to thioflavin‑S in living cells
We have shown recently that thioflavin-S (Th-S) staining 
of living bacterial cells can be used to detect the presence 
of intracellular amyloid-like structures as well as to find 
inhibitors that interfere with amyloid formation [55, 56]. 
The staining of cells expressing PrPWT and PrP90–231 was 
monitored using fluorescence microscopy. As it can be 
observed in Fig. 5, induced cells exhibited a green fluo-
rescent background with fluorescent foci located at the 
cell poles, suggesting that these proteins adopt amyloid-
like conformation in bacterial IBs. In contrast, induced 
cells containing an empty plasmid exhibited only residual 
fluorescence.
Amyloid properties of PrPWT and PrP90–231 IBs
We evaluated the binding of purified PrP IBs to the 
amyloid diagnostic dyes CR and Th-T to confirm that 
the prevalent β-sheet in these aggregates has an amy-
loid-like nature and to further explore if the IBs would 
present different amyloid properties. To evaluate the 
specific contribution of PrP IBs in these assays, relative 
to that of other proteins possibly present in this fraction, 
Fig. 3 Secondary structure analysis of PrPs IBs by ATR-FTIR. The 
secondary structure content of PrPWT (a) and PrP90−231 (b) inside the 
IBs was determined following ATR-FTIR absorbance of dry samples in 
the amide I region of the infrared spectrum (solid black line). Spectral 
components in the Fourier deconvoluted FTIR spectra (dashed gray 
line) are shown as solid gray lines (bands 1–5). The area and position of 
the correspondent bands are indicated in Table 1
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cells bearing the same plasmid without any insert were 
induced and the insoluble fraction purified in the same 
manner than those containing the PrP cDNAs and used 
as negative control.
The absorbance of CR increases and the spectrum 
maximum red-shifts in the presence of amyloid-like 
structures [15]. We calculated the amount of CR bound 
in relation to the negative control (see “Methods”). We 
observed a ~tenfold increase for PrPWT IBs and sevenfold 
increase for PrP90–231 IBs in relation to the control insolu-
ble fraction (Fig. 6a).
ThT fluorescence emission increases significantly when 
the dye binds to amyloid fibrils [57]. Both PrPs IBs pro-
mote a strong increase in Th-T fluorescence (Fig.  6b). 
In agreement with CR data, PrPWT IBs promote a larger 
increase in Th-T fluorescence (eightfold) than the pro-
moted by PrP90–231 IBs (3.5-fold), whereas the negative 
control did not induce any significant increase in fluores-
cence emission relative to free Th-T (Fig. 6b). Although 
these two PrP IBs possesses similar secondary struc-
ture content, these data indicate that murine PrPWT and 
PrP90–231 adopt amyloid-like structures when they aggre-
gate intracellularly in bacteria, displaying, however, dif-
ferent fibrillar structures. Indeed, it is known that mature 
fibrils of different PrP species, like hamster or mice, have 
similar secondary structures but show variation in fibril-
lar morphology [58].
Table 1 Assignment of secondary structure components of purified E. coli PrPWT and PrP90−231 IBs in the amide I region 
of ATR-FTIR spectra
PrPWT IBs PrP90−231 IBs
Band (cm−1) Area (%) Secondary structure Band (cm−1) Area (%) Secondary structure
1621 16 β-Sheet 1623 23 β-Sheet
1634 25 β-Sheet 1638 20 β-Sheet
1655 40 Unordered/α-helix 1656 39 Unordered/α-helix
1677 15 β-Sheet/turns 1678 14 β-Sheet/turns
1692 4 β-Sheet 1693 4.5 β-Sheet
Fig. 4 PrPs IBs present different stability against urea treatment. 
Solubilization of PrPs IBs (OD350 = 1.0) at equilibrium in the presence 
of increasing concentrations of urea, monitored by light scattering at 
350 nm at room temperature. Values shown are the mean ± SD
Fig. 5 Th-S staining in intact bacterial cells expressing PrPs. Bacteria expressing recombinant PrPs (b PrPWT; c PrP90–231) or containing an empty 
plasmid (control) (a) were stained with Th-S and observed at ×40 magnification by fluorescence microscopy to visualize the green fluorescence 
characteristic of amyloid intracellular structures. Arrows indicate the position of IBs
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Amyloid morphology of PrPs IBs
Transmission electron microscopy (TEM) was used to 
investigate the morphology of PrPWT IBs and PrP90–231 
IBs. Interestingly enough, we were able to observe amy-
loid fibrils in PrPWT IBs, without any previous treatment 
with proteases or sonication, coexisting with less ordered 
aggregates (Fig. 7a, b). For the C-terminal PrP IBs (PrP90–
231) we found uniformly shaped aggregates, likely corre-
sponding to prefibrillar structures, similar to aggregates 
populated upon nucleic acid-induced PrPWT aggregation 
(Fig. 7c, d) [36]. The different morphology of both aggre-
gates fits well with their different stability and binding to 
amyloid dyes. The amyloid fibrils detected in PrPWT IBs 
show lateral association and display a ribbon-like assem-
bly composed of two or more aligned non-twisted flat fil-
aments (Fig. 7b). These structural features resemble those 
of in  vitro-formed amyloid fibrils by purified recombi-
nant PrPs (see Fig.  8). In addition, we found also single 
filaments (Fig. 7a, b). This fibrillar disposition is normally 
found in in  vitro-formed PrP amyloids [59]. The fibrils 
found in PrPWT IBs possess variable widths and may 
show some curvature, a feature of ribbon-like assem-
blies. Some ribbons were observed splitting apart either 
at their edges or at the middle, evidencing that they were 
still formed by individual protofibrils (Fig. 7b). We could 
also observe that some ribbons are associated with each 
other and form fibrils with a dichotomous pattern, a 
characteristic well described by Makarava et  al. in 2006 
for mouse PrP amyloid fibrils formed in  vitro [58] (see 
Figs. 7a, b, 8, 9). This morphology was seen mostly during 
the nucleation phase of the fibril polymerization and was 
difficult to find during the subsequent elongation phase. 
Therefore, we conclude that this morphology represents 
a stage of early lateral association rather than dissociation 
of preformed fibrils into protofilaments [58]. In this same 
work, Makarava et  al. showed well distinguishable sub-
sets of fibrils formed by the hamster PrP under identic 
solvent conditions. It thus suggests that the murine PrP 
aggregates freely formed inside bacteria in our work can 
reproduce the same aggregation pathway in vitro without 
the need of a specific condition, such as buffer, pH, tem-
perature and agitation. This polymorphism within fibrils 
has been attributed to the variable number of constitu-
tive protofilaments and distinct modes of their lateral 
association within mature fibrils [58, 60]. In fact, scrapie 
fibrils derived from animals with prions diseases were 
also found to display high levels of polymorphism [11, 
61, 62]. Thus, PrPWT IBs constitute a bacterial reservoir 
of different PrP amyloid structures that coexist with more 
disordered aggregates all formed by the same sequence, 
exemplifying thus conformational diversity. The striking 
different morphology of PrP90–231 IBs and PrPWT strongly 
suggests that the N-terminal PrP is a major contributor 
to the formation of the detected intracellular ordered 
amyloid-like assemblies.  
Amyloid seeding capacity of PrPWT IBs
The kinetics of amyloid fibril formation usually follows 
a sigmoidal curve that reflects a nucleation-dependent 
growth mechanism [63]. As expected, the in  vitro con-
version of purified PrPWT into fibrils follows this kinetic 
scheme (Fig.  8), with a lag phase of ~7  h, which corre-
sponds to the formation of the initial nuclei and that is 
followed by polymerization or fibril growth, as confirmed 
by TEM imaging of the solution during the aggrega-
tion reaction (Fig.  8). Seeded protein aggregation is a 
well-established mechanism for in  vivo amyloid fibril 
formation and underlies prion propagation [64, 65]. 
Accordingly, in the presence of 2  % preformed fibrils, 
the lag phase of the reaction is shortened to ~3.5  h. To 
test if the detected amyloid-like structures in PrPWT IBs 
were able to template the conversion of its respective 
soluble species into amyloid fibrils, we performed the 
aggregation reaction in the presence of limited amounts 
Fig. 6 Specific binding of amyloid dyes to PrPs IBs. a CR bind-
ing assay in the presence of PrPs IBs and control insoluble fraction 
(OD350 = 1.0); the extent of binding is calculated as described in 
“Methods”. b Fluorescence emission spectrum of Th-T in the presence 
of PrPs IBs and control insoluble fraction (OD350 = 0.1). Samples were 
excited at 445 nm and emission was collected from 480 to 580 nm. 
Both assays were done in PBS
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of preformed purified PrPWT IBs (Fig.  10). Interestingly 
enough, the effect exerted by IBs on fibril formation 
kinetics is similar to that promoted by the correspond-
ing PrPWT amyloid fibrils seeds, reducing the lag phase 
of the reaction to ~2  h. However, in PrPWT IBs seeded 
reactions large aggregates that cannot be maintained 
in solution appear to accumulate after 12  h (720 min) 
of polymerization (Fig.  10). In contrast to amorphous 
aggregation, amyloid formation is a specific process 
that can only be seeded by sequentially and structurally 
homologous fibrils [66]. To evaluate if such selectivity 
also applies in the case of PrP IBs, we performed cross-
seeding experiments, seeding the aggregation reaction 
of initially soluble PrPWT with preformed and purified 
PrP90–231 IBs. Importantly, the presence of PrP90–231 IBs 
does not have any noticeable impact on the nucleation 
reaction, the overall kinetics resembling those of a non-
seeded reaction (Fig. 10), thus confirming that a specific 
molecular recognition between soluble and fibrillar states 
is a requirement for seeding and that in the case of PrPWT 
the N-terminal tail might play a crucial role in this pro-
cess. Accordingly, it has been previously observed by 
high-pressure FTIR that the N-terminal domain modu-
lates PrP misfolding and aggregation [67].
We analysed the morphology of the aggregates present 
in the final reaction of seeded and unseeded kinetics by 
Fig. 7 Morphological analysis of PrPs inside IBs. Fresh and intact PrPWT (a, b) and PrP90–231 (c, d) IBs observed by negative staining and transmission 
electron microscopy display amyloid-like structures. Scale bars 0.5 μm (a), 0.2 μm (b), 0.2 μm (c, d). The arrows indicate single filaments; the asterisks 
mean unzipped filaments and the hash indicates the initial step of a protofibril formation
Page 8 of 16Macedo et al. Microb Cell Fact  (2015) 14:174 
TEM. In agreement with spectroscopic data, the pres-
ence of PrPWT IBs and fibrils at the beginning of the reac-
tion resulted in an increased number of amyloid fibrils in 
respect to non-seeded reactions or reactions seeded with 
PrP90–231 IBs. However, the acceleration of the fibrillation 
promoted by PrPWT fibrils and especially by PrPWT IBs 
results in the formation of apparently amorphous mate-
rial tightly associated to the newly formed amyloid fibrils 
(Fig. 9). Interestingly, we could see after seeding PrP amy-
loid formation with PrPWT IBs the presence of twisted 
fibrils (Fig.  9). Several early prion studies reported that 
filamentous structures were found in scrapie-infected 
rodent brain [68, 69]. In 1981, one report has called 
attention to helical fibrils formed by the twisting of two 
or four filamentous structures; they were found in prepa-
rations from brains of scrapie-infected rodents [70]. The 
ultrastructural morphology of these fibrils was reported 
to be different from that of many amyloids [71]. Nowa-
days, there are many reports providing information about 
the PrP twisted fibrillar structures [60].
Using small amounts of the PrPWT IBs seeded solution 
for re-seeding PrPWT soluble protein results in formation 
of visible fibrillar material that, when analysed by TEM, 
displays typical amyloid morphology coexisting with 
more amorphous material, confirming thus the striking 
ability of PrPWT IBs to effectively propagate soluble pro-
tein conformational conversion into amyloid structures 
(Additional file 2).
PrPs IBs display a proteinase K resistant core
Proteinase K (PK) is a protease normally used to map the 
protected core of amyloid fibrils. Despite its high activity 
for cleaving peptide bonds, PK cannot attack the highly 
packed backbones in an amyloid β-sheet structure. In 
contrast to soluble forms of PrPs, which are PK-sensitive, 
aggregated forms of PrP are known to have a PK-resist-
ance profile that can be dependent on the in vitro aggre-
gation conditions or even on the different in vivo sources 
from where they were extracted (such as diseased brains) 
[49, 72–75]. To verify the PK-resistance of the two dif-
ferent PrP aggregated deposits formed inside the cell, 
we evaluated the PK digestion of PrP IBs by tricine SDS-
PAGE (Fig. 11). There were differences in the PK-diges-
tion pattern between the two PrP IBs. Upon incubation 
of PrPWT IBs with PK, the resistant fibrillar core is visu-
alized as a major band with 16 kDa, which corresponds 
to the PrP C-terminal domain as evidenced by western 
blot analyses with the anti-PrP antibody R20 that rec-
ognizes a C-terminal epitope in PrP (residues 218–232) 
[76] (Additional file 3). This fragment possesses the same 
apparent molecular weight of the C-terminal domain 
(residues 90–231) (16 kDa), indicating that the N-termi-
nal domain was cleaved and the rest of the protein was 
in a protected conformation. Most of the resultant frag-
ments of PK-digested PrPWT IBs, which vary from ~15 
to 6 kDa were labeled by R20, and even after 60 min of 
reaction the larger fragment (16 kDa) persists (Fig. 11a). 
Indeed, the PK-resistant core of the pathogenic PrPSc 
corresponds also to the PrP C-terminal domain [14]. 
The PK resistance of PrPWT IBs is comparable with the 
PK-resistant form of PrPSc. In PrP amyloid IBs we stud-
ied here, the 16  kDa band resisted PK treatment under 
conditions that are commonly used for PK reactions with 
the scrapie brain homogenates (incubation for 1 h at neu-
tral pH) [77, 78]. In addition, this same resistant frag-
ment (16 kDa) is also observed upon PK-digestion of the 
in vitro-formed PrP amyloid fibrils [79]. In contrast, PK-
digestion of PrP90–231 IBs showed a different profile; after 
30  min of PK-treatment the apparent 16  kDa fragment 
was completely degraded, and the remaining resistant 
Fig. 8 Evolution of PrPWT aggregates morphology during in vitro aggregation. After purification and refolding PrPWT was converted into amyloid 
fibrils as described in “Methods”. The aggregates morphology was assessed at different times by negative staining and transmission electron micros-
copy. Scale bars 0.2 μm (10 h), 0.5 μm (24 h), and 0.5 μm (72 h)
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Fig. 9 Morphology of PrPWT aggregates at the end of the aggregation kinetics. Aggregates were collected at the end (~19 h) of non-seeded (a), 
seeded (c–f) and cross-seeded (b) reactions (Fig. 10) and they were monitored by negative staining and transmission electron microscopy. Scale 
bars 2 μm (a); 0.5 μm (b); 1.0 μm (c); 0.2 μm (d); 2 μm (e); 1 μm (f)
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fragments have lower molecular mass (Fig.  11b). These 
PrP IBs do not possess the same conformation and, thus, 
as expected, differ in their biochemical and biophysical 
properties. Recently, it was shown that full-length recom-
binant PrP (23–231) can aggregate into a β-sheet-rich 
oligomeric species (~12 PrP molecules), and that the pro-
tein N-terminal region (23–90) was necessary for the for-
mation of this oligomer [80]. At the same condition, PrP 
lacking part of the N-terminal region (PrP91-231) aggre-
gated into heterogeneous species [80]. It is increasingly 
recognized the essential role of the N-terminal  domain 
in directing PrP intermolecular association and in pro-
moting the stability and proper folding of the C-terminal 
domain [80–82]. Taken together, this result is in good 
agreement with the lower stability we have shown to 
extracted PrP90–231 IBs relative to PrPWT IBs (Fig. 4).
To confirm the conformational diversity exhibited by 
PrP90–231 and PrPWT we explored whether their differ-
ently protected amyloid cores display different cyto-
toxic properties. To this aim PrP IBs where digested 
with PK for 60  min, the protease was inactivated and 
the digested aggregates were administered to neuro-
blastoma SH-SY5Y cells. The combination of SYBR 
green and propidium iodide (PI) staining allows assess-
ing the cell viability by confocal fluorescence micros-
copy, as viable cells are permeable to SYBR green and 
PI only enters cells with permeabilized membranes 
corresponding to dead cells. The impact of aggregates 
in cell morphology was also monitored (Fig.  12). Cells 
treated with inactivated PK were used as negative con-
trols. Cells treated with the PK-resistant PrP90–231 core 
exhibited normal morphology and were not stained 
with PI, indicating that it does not exert significant tox-
icity. In contrast, the PK-resistant PrPWT core was neu-
rotoxic, since its presence resulted in cell death  (cells 
were stained with PI) and in abnormal cell morphology. 
Although the prion infectious region is attributed to the 
resistant 90–231 core (PrP27-30 in  vivo), we did not 
see neurotoxic activity for PK-digested PrP90–231 IBs, 
only for digested PrPWT IBs. We showed here that the 
protease-resistant region of the PrPWT IBs, after 60 min 
of reaction, belongs to the C-terminal domain in con-
trast to PrP90–231  IBs digestion,  which renders smaller 
fragments that do not bind to PrP antibody (R20) 
(Additional File 3).  One might speculate that the larg-
est fragment of the C-terminal resistant to PK-digestion 
(the 16 kDa fragment) is necessary to retain cytotoxic-
ity; this fragment might have its intact disulphide bridge 
which is well known to be necessary to cause prion 
diseases [83]. Further experiments will be required to 
address which are the residues involved in the toxic 
conformations we have seen for these PrPWT  IBs PK-
resistant core. Therefore, they are not the same species, 
and thus, are expected to result in different cytotoxic 
effects. Probably, the low molecular weight fragments 
derived from PrP90–231 IBs are not properly folded into a 
toxic conformation. Moreover, the amount of PK-resist-
ant fragments for both PrP constructs differs, as the 
sensitivity to PK is depends on the aggregated structure.
Conclusions
Prions are misfolded, self-propagating and infectious 
proteins. The bacterial inclusion bodies formed by fungal 
prions, such as HET-s PFD, Ure2p and Sup35-NM have 
been shown to display an amyloid fold and to be infec-
tive. This ability to embrace potentially harmful mis-
folded polypeptides into insoluble deposits seems to be 
a strategy mechanism perpetuated along the evolution 
from prokaryotic bacteria to highly complex eukaryotic 
organisms. We showed here for the first time that the IBs 
formed by mammalian prion proteins are also enriched 
in seeding competent amyloid-like structures, supporting 
the formation of prion-like conformations inside bacte-
ria. Moreover, these aggregates display conformational 
diversity, thus becoming an interesting and simple model 
to study how this property can be modulated in vivo by 
the quality control machinery. Since PrP accumulates in 
IBs at high levels and these biological particles are eas-
ily purified, it is suggested that they might become a con-
venient source to obtain prion particles. It is clear that 
the bacterial cytosol where these aggregates are formed 
Fig. 10 Aggregation kinetics of PrPWT. The aggregation reactions of 
0.5 mg/mL of purified and refolded rPrPWT were carried out under 
constant agitation at 600 RPM and 37 °C. In vitro preformed fibrils 
(2 %) or PrPs IBs (final OD350 = 0.1) were used for seeding and cross-
seeding assays. PrP fibrilization (black line) as a function of time, exhib-
its a typical nucleation-elongation profile. The lag phase is reduced 
in the presence of pre-aggregated homologous protein, either PrPWT 
fibrils (blue line) or PrPWT IBs (red line). Cross-seeding with PrP90–231 IBs 
(green line) did not affect the fibrilization extent and kinetics
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differs from that of eukaryotic cells; however, the poten-
tiality of these inside-the-cell formed amyloid parti-
cles to adopt infective conformations is, in our opinion, 
much higher than the one of the aggregates formed by 
the purified recombinant protein in vitro after complete 
denaturation and refolding procedures. In addition, as 
already shown for other amyloids [15], PrP-producing 
bacterial cells can potentially be used for the easy and 
cheap screening of anti-aggregation compounds able to 
prevent intracellular PrP amyloid-like aggregation, being 
thus useful in the early stages of discovery of anti-prionic 
drugs.
Methods
Prion proteins expression and purification
E. coli C43 (DE3) cells were transformed with plasmids 
(pET-28 b) encoding the murine wild-type prion protein 
(PrPWT) encompassing residues 23–231 and the murine 
Fig. 11 PK proteolysis of PrPs IBs. Tricine SDS-PAGE analysis of a PrPWT IBs and b PrP90–231 IBs after incubation with 2.5 µg/mL PK at 37 °C for the 
indicated times. The smaller fragments remaining after PK proteolysis indicate a resistant core of these PrP IBs. The molecular weight ladder (MW) is 
placed offset for clarity. The arrows indicate C-terminal PrP fragments
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PrP C-terminal domain residues 90–231 (PrP90–231), 
both containing a histidine-tag. Cells were grown aero-
bically in liquid Luria–Bertani (LB) medium containing 
appropriate antibiotics in a rotary shaker at 37  °C and 
250 RPM. Overnight cultures were diluted 100-fold in LB 
and allowed to grow to an OD600 = 0.7. At OD600 = 0.7, 
expression was induced with 1  mM isopropyl-1-thio-β-
d-galactopyranoside (IPTG). Cells were harvested after 
overnight induction (18–20  h), centrifuged, resuspended 
in 60 mL of buffer U (8 M urea, 10 mM Tris–HCl, 100 mM 
NaH2PO4, 10  mM reduced glutathione, pH 8.0). After 
sonication and centrifugation, the soluble protein fraction 
was added to 5 mL of HisTrap FF prepacked column (GE 
Healthcare) and washed with 30 mL of buffer U. On-col-
umn oxidative refolding was performed by applying for 2 h 
a 160 mL-gradient of buffer U to buffer B (10 mM Tris–
HCl, 100  mM NaH2PO4, pH 8.0). Then, the column was 
washed with 50  mL buffer B. Unspecific bound proteins 
were removed from the column with 50 mL of 50 mM imi-
dazole in buffer B. The recombinant proteins PrPWT and 
PrP90–231 were eluted with buffer E (10 mM Tris, 100 mM 
NaH2PO4, 750 mM imidazole, pH 5.8). Histidine tail-fused 
PrP was dialyzed against milliQ water at least two times. 
The histidine tail was removed from the prion protein 
using thrombin (1:1000). The cleavage reaction was carried 
out at room temperature for 2 h. After thrombin cleavage, 
the sample was repurified in the HisTrap column. Finally, 
the protein solution was dialyzed against milliQ water two 
times to remove any remaining salt. 15 % SDS-PAGE anal-
ysis revealed more than 95 % of purity.
PrPWT and PrP90–231 IBs extraction
IBs were purified from IPTG-induced cells harbouring 
the pET-28(b)/PrPWT plasmid, the pET-28(b)/PrP90–231 
plasmid and vector alone by detergent-based procedures. 
IBs were purified from induced cell extracts by detergent-
based procedures as previously described [17]. Briefly, 
cells in a 10 mL culture were harvested by centrifugation 
at 12,000g (at 4 °C) for 15 min and resuspended in 200 µL 
of lysis buffer (50  mM Tris–HCl pH 8.0, 1  mM EDTA, 
100  mM NaCl), plus 30  µL of 100  mM protease inhibi-
tor PMSF and 6 µL of a 10  mg/mL lysozyme solution. 
After 30  min of incubation at 37  °C under gentle agita-
tion, Nonidet-P40 was added at 1  % (v/v) and the mix-
ture was incubated at 4 °C for 30 min. Then, DNase I and 
RNase were added to a final concentration of 25 μg/mL 
and 3 µL of 1 M MgSO4 was added. The resulting mix-
ture was further incubated at 37  °C for 30  min. Protein 
aggregates were separated by centrifugation at 12,000g at 
4  °C for 15 min. Finally, IBs were washed once with the 
same buffer containing 0.5 % Triton X-100 and once with 
phosphate buffered saline (PBS). After a final centrifuga-
tion at 12,000g for 15 min, pellets were stored at −20 °C 
until analysis. The frozen pellets were reconstituted in 
PBS. SDS-PAGE analysis revealed that in all cases the 
murine prion proteins were the major polypeptidic com-
ponents of the aggregates. Prion proteins concentration 
in IBs was estimated using image densitometry software 
Fig. 12 Cytotoxicity of the PK-resistant core of PrP IBs visualized by 
confocal microscopy. Confocal fluorescence microscopy images of 
SH-SY5Y cells stained with SYBR green or propidium iodide (PI). Cells 
were treated with PK-derived fragments of PrPWT IBs (panels c–j), or 
PrP90−231 IBs (k, l). All samples were incubated with PK for 1 h at 37 °C 
and PK was inactivated before applying to cells. Inactivated PK in PBS 
was used as control (a, b). Representative images of two independ-
ent experiments done in duplicate are shown. Further details are 
described in the “Methods”
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ImageJ in the SDS-PAGE gel analysis in comparison with 
the respective dosed purified protein. We performed the 
same procedures with cells extracts of bacteria contain-
ing an empty plasmid as control IBs.
Secondary structure determination
Attenuated total reflectance (ATR)-Fourier Transformed 
Infrared spectroscopy analyses of PrPWT and PrP90–231 
IBs were performed using a Nicolet 6700 IR spectrom-
eter (Thermo Scientific, USA) equipped with an ATR 
accessory. Dried samples were applied directly to the 
ATR crystal to be analysed. Each spectrum consisted of 
128 accumulated scans, measured at a spectral resolu-
tion of 4 cm−1 within the mid-IR range (4000–675 cm−1). 
Fourier deconvolution of the FTIR spectra was per-
formed with a resolution enhancement factor of 1.6 and 
a bandwidth of 21  cm−1. Peak position and curve fit-
ting were determined with OMNIC™ software v. 8.0 
(Thermo Scientific WI, USA) with a mixed Gaussian-
Lorenztian function, allowing assignment of different 
secondary structure components in the amide I range 
(1700–1600 cm−1) [47, 48, 67].
Congo red binding
To get insights into the amyloid nature of the PrPWT 
and PrP90–231 IBs, CR binding assays were performed. 
The interaction of 20 μM CR with the purified IBs (final 
OD600: 0.1) was tested using a Cary100 UV/Vis spectro-
photometer (Varian, Palo Alto, CA, USA). CR binding 
was quantified by the equation: CR bound = Abs540nm/25, 
295 − ABS477nm/46,306 [84]. The extent of amyloid struc-
ture was measured by the increase of CR bound to PrP 
IBs in relation to control IBs [IBs purified from IPTG-
induced cells harbouring only the pET-28(b) plasmid].
Thioflavin T (Th‑T) binding assay
Th-T binding was used to probe amyloid presence in 
the samples. Incubation of 30 μM Th-T with PrPWT IBs 
and PrP90–231 IBs (final OD600: 0.1) or the correspond-
ent amyloid fibrils was recorded using a Jasco FP-8200 
spectrofluorometer (Jasco Inc, MD, USA) with an exci-
tation wavelength of 445 nm and emission range from 
480 to 580  nm at 37  °C in PBS. Five individual scans 
were averaged for each measurement. The intensity of 
the spectra at the 482 nm maximum was recorded as an 
indication of the extent of amyloid conformation in the 
aggregates.
Thioflavin‑S binding in living cells
Detection of thioflavin-S (Th-S) binding was performed 
in living cells expressing PrPWT, or PrP90–231 and control 
non-induced cells. Bacterial cells were washed with PBS 
buffer and diluted at an OD600 of 0.1. Th-S was added at 
125  µM final concentration; cells were then incubated 
for 1 h and washed twice with PBS. Cells were placed on 
top of a microscope slide and covered with a cover slip. 
Photographs were acquired at 40-fold magnification 
under UV light in a Leica fluorescence microscope (Leica 
DMRB, Heidelberg, Germany).
Chemical denaturation
For stability assays, purified PrPWT and PrP90–231 IBs were 
prepared at final OD350 =  1 in PBS containing selected 
concentrations of urea ranging from 0 to 8 M. The reac-
tions were allowed to reach equilibrium by incubating 
them for 12 h at room temperature. The fraction of solu-
ble protein (fS) was calculated from the fitted values using 
equation: fS = 1 −  ((yS − y)/(yS − yA)), where yS and yA 
are the absorbance at 350  nm of the soluble and aggre-
gated protein, respectively, and y is the absorbance of the 
protein solution as a function of the denaturant concen-
tration. The value m1/2 was calculated as the denaturant 
concentration at which fS  =  1/2. OD350 changes were 
monitored with a Cary400 Varian spectrophotometer.
Transmission electron microscopy (TEM)
Each sample (20 μL) was applied to a carbon coated cop-
per grid, and after 5 min the grid was washed with MilliQ 
water. Samples were stained with 2 % (w/v) uranyl acetate 
for 1 min and then washed again. Images were collected 
on a Jeol 1200 microscope (Boston, MA, USA) operating 
at 80 kV.
In vitro conversion of PrP into amyloid fibrils
To target amyloid fibril formation, PrP solutions were 
prepared immediately before use by resuspending lyo-
philized purified PrPWT powder in 4 M GdnHCl, 0.02 M 
thiourea, and 0.1 M MES, pH 6.0, in a protocol adapted 
from previous studies [59]. Samples were centrifuged 
at 12,000g for 5  min and the protein concentration 
was determined by its extinction coefficient at 280  nm 
(63,495  M−1  cm−1), calculated from the PrPWT primary 
sequence in http://web.expasy.org/protparam/. The 
fibrillation reactions of 0.5 mg/mL PrP were carried out 
in 1.5-ml conical low-binding plastic tubes up to a total 
reaction volume of 0.6 ml at 37 °C with continuous shak-
ing at 600  rpm for at least 3 days using an Eppendorf 
Thermomixer Comfort (Eppendorf, USA). Aliquots from 
each sample were taken over time.
Seeding assays
PrP aggregation departing from monomeric recombinant 
PrP was monitored by measuring the transition from 
non-aggregated to aggregated state by following light 
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scattering at 350 nm in a Jasco FP-8200 spectrofluorom-
eter (Jasco Inc, MD, USA). The polymerization reactions 
showed typical nucleation-elongation kinetics of amyloid 
formation. The reactions were carried out with 0.5  mg/
mL of soluble purified PrPWT in 4  M GdnHCl, 0.02  M 
thiourea, and 0.1 M MES pH 6.0 using 1 cm-path length 
quartz cuvette in a total reaction volume of 1 mL at 37 °C 
with continuous shaking at 600  rpm using micro-stir 
bars. In the seeding assays, a solution of PrPWT IBs resus-
pended in PBS with OD350 of 10.0 were sonicated for 
10 min, and then diluted 100-fold (final OD350 = 0.1) at 
the beginning of the reaction. The seeding ability of 2 % 
preformed fibrils (after 10  min of sonication) was also 
evaluated. Cross-seeding assays were performed in the 
same manner by adding a sonicated solution of PrP90–231 
IBs (final OD350 = 0.1) to initially soluble PrPWT.
Confocal microscopy and image processing
Confocal images of human neuroblastoma (SH-SY5Y) 
cell cultures were captured in complete medium at 37 °C, 
using a laser scanning confocal microscope (Leica TCS 
SP2 AOBS equipped with a HCX PL APO 63 × 1.4 oil, 
immersion objective, Germany). Briefly, SH-SY5Y cells 
were seeded in 35  cm2 plates (Mat Tek) with approxi-
mately 30 % of confluence in complete medium and incu-
bated for 72 h in the presence of sterile PBS buffer + PK 
(positive control) and the PK-resistant core of the PrPs 
IBs. Proteinase K was inactivated by boiling all solu-
tions before applying them to cultured cells. Cells were 
incubated with 0.5  μg/mL SYTO green and 10  μg/mL 
propidium iodide (PI) (Molecular Probes) for 15 min at 
37 °C and washed twice with PBS buffer. Cell morphology 
was analysed by confocal fluorescence microscopy using 
an orange diode (588–715  nm emission collected) and 
a UV laser (excited at 350 nm and collected at 405 nm). 
Two independent experiments, both in duplicate were 
done and the entire field of each plate was observed at 
the microscope.
Proteinase K (PK) resistance assay
The PK concentration in this assay was optimized in 
preliminary experiments (not shown). PrPWT IBs and 
PrP90–231 IBs at final OD350 of 0.5 were incubated with 
PK (Sigma-Aldrich, USA) at final concentration of 2.5 μg/
mL in PBS for 1 h at 37 °C. Aliquots of PK digestion were 
taken at every 10 min and the reaction quenched by the 
addition of the same amount of 4 times concentrated 
denaturing sample buffer. Samples were heated at 95  °C 
for 5 min and analysed by Tris–Glycine SDS-PAGE. The 
assay with soluble purified recombinant PrP was per-
formed in the same manner [85].
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